Prediction of Local Drug Exposure of Dry Powder Inhaler CXG87 (budesonide/formoterol) Using Physiologically‐Based Pharmacokinetic Model

Documenti analoghi

• Clinical and Physiologically Based Pharmacokinetic Model Evaluations of Adagrasib Drug–Drug Interactions
  di: Cornelius Cilliers, et al.
  Pubblicazione: (2024)
• Predicting Maternal and Fetal Exposures of Elexacaftor–Tezacaftor–Ivacaftor during Pregnancy through Physiologically Based Pharmacokinetic Models
  di: Eunjin Hong, et al.
  Pubblicazione: (2025)
• Optimizing Maternal and Fetal Antibody Exposure and Dosing Regimens During Pregnancy Using a Physiologically Based Pharmacokinetic Model
  di: Miramar Sami Kardouh, et al.
  Pubblicazione: (2025)
• Application of Physiologically Based Pharmacokinetic Modeling to Inform Dose Selection of Mezigdomide in a Phase I Drug–Drug Interaction Study
  di: Joseph Burnett, et al.
  Pubblicazione: (2025)
• Physiologically Based Pharmacokinetic Modeling to Investigate the Disease‐Drug–Drug Interactions between Voriconazole and Nirmatrelvir/Ritonavir in COVID‐19 Patients with CYP2C19 Phenotypes
  di: Peile Wang, et al.
  Pubblicazione: (2024)